Formoterol-fumarate-racemic-Formoterol-fumarate-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEFormoterolfumarateCat.No.:HY-B0010CASNo.:43229-80-7Synonyms:(±)Formoterolfumarate分?式:C??H??N?O?.?/?C?H?O?分?量:402.44作?靶點:AdrenergicReceptor作?通路:GPCR/GProtein;NeuronalSignaling儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:≥50mg/mL(124.24mM)H2O:<0.1mg/mL(insoluble)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.4848mL12.4242mL24.8484mL5mM0.4970mL2.4848mL4.9697mL10mM0.2485mL1.2424mL2.4848mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(6.21mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(6.21mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:2.5mg/mL(6.21mM);Clearsolution;NeedwarmingBIOLOGICALACTIVITY?物活性Formoterol((±)Formoterol)fumarate長效的β2-腎上腺素受體激動劑。REFERENCES[1].ArunJJ,LodhaR,KabraSK.Bronchodilatoryeffectofinhaledbudesonide/formoterolandbudesonide/salbutamolinacuteasthma:adouble-blind,randomizedcontrolledtrial.BMCPediatr.2012Mar7;12:21.[2].CopeS,KraemerM,ZhangJ,Efficacyofindacaterol75μgversusfixed-dosecombinationsofformoterol-budesonideorsalmeterol-fluticasoneforCOPD:anetworkmeta-analysis.IntJChronObstructPulmonDis.2012;7:415-20.[3].TaconCE,NewtonR,ProudD,Rhinovirus-inducedMMP-9expressionisdependentonFra-1,whichismodulatedbyformoterolanddexamethasone.JImmunol.2012May1;188(9):4621-30.[4].ZhongN,LinJ,MehtaP,Real-lifeeffectivenessofbudesonide/formoterolmaintenanceandrelievertherapyinasthmapatientsacrossAsia:SMARTASIAstudy.BMCPulmMed.2013Apr4;13(1):22.[5].ShinkaiN,TakasunaK,TakayamaS.Tocolyticactivityofformoterolagainstprematuredeliveryinmice.JPharmPharmacol.2002Dec;54(12):1637-43.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresear